Merck matches Roche in search for next cancer immunotherapy
Merck became an undisputed leader in cancer immunotherapy thanks to its success with Keytruda, now one of the industry’s best-selling drugs. Now, the pharma is showcasing three experimental drugs that may come next.
One is a new type of immune-boosting drug that blocks a cell receptor protein known as TIGIT, which may improve treatment response to Keytruda in patients with metastatic lung cancer. The others include an immunotherapy in early testing for solid tumors and an oral tablet for kidney cancer.
